Mantik KEK, Kim S, Gu B et al (2023) Repositioning of anti-diabetic drugs against dementia: insight from molecular perspectives to clinical trials
Personalized care, made easy Step 1 Get approved Share your health history, lifestyle, and goals so we can better understand you and create care that truly fits your needs
Glucagon-like peptide-1 analogs mitigate neuroinflammation in alzheimers disease by suppressing NLRP2 activation in astrocytes
For example, the semaglutide pen is not recommended to be used more than 56 days once started, he says
Contact your healthcare provider if you experience minimal improvement after reaching maintenance dose for 12-16 weeks, including persistently elevated blood glucose or lack of at least 5% body weight reduction
Patients who value FDA-approved drugs and closer medical supervision will likely feel more confident with a more clinically intensive program